MedTrace Logo

One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL

NCT05728424 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 246

Last updated 2023-02-15

No results posted yet for this study

Summary

1. To assess the efficacy of the duration of Vonoprazan based triple regimen (one versus two weeks), in the eradication of H-pylori among patients attending gastroenterology clinics of Karachi, Pakistan.
2. To assess the improvement in the quality of life of patients receiving Vonoprazan as part of the triple regimen.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Vonoprazan, Amoxicillin, Levofloxacin

No additional information

Sponsors & Collaborators

  • Searle Pharmaceuticals

    collaborator UNKNOWN

  • Aga Khan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-20
Primary Completion
2023-04-01
Completion
2023-05-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05728424 on ClinicalTrials.gov